Loading...
Regional Anticoagulant Adoption Will Drive Long Term Opportunity In Renal Replacement Therapy
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
15 Dec 25
Views
24
15 Dec
US$0.82
AnalystConsensusTarget's Fair Value
US$3.25
74.9% undervalued intrinsic discount1Y
59.9%7D
5.2%1Y
59.9%7D
5.2%You can edit this narrative until Dec 16 7:05 AM. Then, changes will post as Updates.
Author's Valuation
US$3.2574.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value